The relationship between IL6 and the kinetics of the ApoB-containing Lipoproteins in people with chronic inflammatory joint disease.

Trial Profile

The relationship between IL6 and the kinetics of the ApoB-containing Lipoproteins in people with chronic inflammatory joint disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Acronyms apoB Kinetics; KALIBRA
  • Most Recent Events

    • 12 Dec 2014 Planned End Date changed from 19 Apr 2015 to 11 Dec 2014 as reported by United Kingdom Clinical Research Network.
    • 12 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 12 Nov 2014 Accrual to date is 80% according to United Kingdom Clinical Research Network
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top